Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Clinical trial NCT00157196 · COMPLETED

Trial details

NCT number: NCT00157196
Sponsor: Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Start date: 2005-04-01
Primary completion: 2007-09-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.